AstraZeneca’s COVID-19 vaccine road to approval has been anything but smooth. Announcing in March a mid-April submission for U.S. approval, that timeline has been pushed back to mid-May, with the company citing the massive dataset as the cause.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,